References
- Schultz J-C, Adamson J-C, Workman WW, NormamTD. Fatal liverdisease after intravenous administration of tetracycline in high dosage. N Engl J Med. 1963; 269: 999–1004.
- Kusselis CT, Peters RL, Edmondson HA. Fatty liver of pregnancy and its relationship to tetracycline therapy. Am J Med. 1965; 38: 359–77.
- Peters RL, Edmondson HA, Mikhelsen WP, Totter D. Tetracycline-induced fatty liver in non pregnant patients: a report of 6 cases. Am J Surg. 1967; 113:622–32.
- Dowling HF, Lepper MH. Hepatic reactions to tetracycline. JAMA. 1964; 188: 307–9.
- Hautekeete ML, Degott C, Benhamou J-P. Microvesicular steatosis of the liver. Acta Clin Belg. 1990; 45: 311–26.
- Burette A, FinetC.PrigogineT, De Roy G, Deltenre M. Acute hepatic injury associated with minocycline. Arch Intern Med. 1984; 144: 1491–92.
- Lewis C, Schenker S, Burton C. Studies on the pathogenesis of tetracycline induced fatty liver. Am J Dig Dis. 1967; 12: 429–38.
- Fresseaux E, Labbe G, Letteron P et al. Inhibition of the mitochondrial oxydation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by the antibiotic. Hepatology. 1988; 8: 1056–62.
- Delakunt C S, Jacobs RT, Stebbins RB, Rierer N. Toxicology of Vibramycin. ToxAppl Pharmacol. 1967; 10: 402.
- Scientific notice of VI BR ATA B (monohydrate of doxycycline) Pfizer S.A. 1987.